Government and Regulations

Restoring Testosterone Levels May Improve Sexual Function

Early findings from Testosterone Trials point to some areas where the therapy can improve seniors’ lives, but also shows little effect on mobility or fatigue.


 

Preliminary results from the Testosterone Trials, a group of studies supported in part by the National Institutes on Aging, suggest that restoring levels of testosterone to those of healthy young men improves the sexual function of seniors, but does not significantly affect mobility and fatigue.

Related: Testosterone Replacement Therapy: Playing Catch-up With Patients

The findings are from the first 3 of 7 double-blind, placebo-controlled trials aimed at determining whether testosterone treatment could alleviate those symptoms. The trials were recommended by the former Institute of Medicine (now the National Academy of Medicine) as a key step before considering larger trials of long-term risks.

In the studies, 790 men aged ≥ 65 years received daily testosterone or placebo via gel. Serum testosterone concentration was measured regularly for 12 months. Testosterone did not significantly affect walking ability, but in all 3 trials walking speed and distance did improve in the testosterone group, compared with the placebo group. Testosterone did not have a significant effect on fatigue, but had “modest favorable” effects on mood. Men in the testosterone group were also more likely to report that they had more energy.

Related: Opioid-Induced Androgen Deficiency in Veterans With Chronic Nonmalignant Pain

“For a long time, there has been interest in whether testosterone is an appropriate therapy for aging-related conditions in men,” said NIA Director Richard Hodes, MD. “This study clarifies questions about some of its potential benefits. As the researchers note, clarifying the risks requires further study.” Participants experienced few adverse events, but too few to draw conclusions about risks in older men, especially given that men at high risk for prostate cancer and cardiovascular disease were not included in the trial.

Recommended Reading

Decrease of Sexual Violence on Military Campuses Is Not Enough
Federal Practitioner
Urologist Workforce Variation Across the VHA
Federal Practitioner
Treatment of Ampicillin-Resistant Enterococcus faecium Urinary Tract Infections
Federal Practitioner
Testosterone Replacement Therapy: Playing Catch-up With Patients
Federal Practitioner
Female Service Members in the Long War
Federal Practitioner
Native Americans Address LGBT Health Issues
Federal Practitioner
Opioid-Induced Androgen Deficiency in Veterans With Chronic Nonmalignant Pain
Federal Practitioner
Ebola Virus Persists in Semen Long Term
Federal Practitioner
Long-Term Surgical Management of Severe Pelvic Injury and Resulting Neurogenic Bladder From an Improvised Explosive Device
Federal Practitioner
Tested Tools to Reduce Catheter-Associated UTIs
Federal Practitioner

Related Articles